Histologic Tumor Type As a Determinant of Survival in Hormone Receptor-positive, HER2-negative, PT1-3 Invasive Ductal and Lobular Breast Cancer

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2023 Nov 23

PMID 37993928

Authors

Menekse Goker

Hannelore Denys

An Hendrix

Olivier de Wever

Koen Van de Vijver

Geert Braems

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of the study was to compare the difference in survival between invasive ductal (IDC) and lobular carcinoma (ILC).

Methods: Data of patients (n = 1843) with a hormone receptor-positive, HER2-negative, pT1-3 IDC or ILC cancer without distant metastasis, treated at the Ghent University Hospital over the time period 2001-2015, were analyzed.

Results: ILC represented 13.9% of the tumors, had a higher percentage of pT3 and pN3 stages than IDC, lymphovascular space invasion (LVSI) was less present and Ki-67 was mostly low. 73.9% of ILCs were grade 2, whereas IDC had more grade 1 and grade 3 tumors. Kaplan-Meier curves and log-rank testing showed a significant worse DFS for ILC with pN ≥ 1 than for their IDC counterpart. In a multivariable Cox regression analysis the histologic tumor type, ductal or lobular, was a determinant of DFS over 120 months (IDC as reference; hazard ratio for ILC 1.77, 95% CI 1.08-2.90) just as the ER Allred score (hazard ratio 0.84, 95% CI 0.78-0.91), LVSI (hazard ratio 1.75, 95% CI 1.12-2.74) and pN3 (hazard ratio 2.29, 95% CI 1.03-5.09). Determinants of OS over ten years were age (hazard ratio 1.05, 95% CI 1.02-1.07), LVSI (hazard ratio 3.62, 95% CI 1.92-6.82) and the ER Allred score (hazard ratio 0.80, 95% CI 0.73-0.89).

Conclusion: The histologic tumor type, ductal or lobular, determines DFS in hormone receptor-positive, HER2-negative, pT1-3 breast cancer besides the ER Allred score, LVSI and pN3.

References

Yeatman T, Lyman G, Smith S, Reintgen D, Cantor A, Cox C . Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. Ann Surg Oncol. 1997; 4(3):198-202. DOI: 10.1007/BF02306610. View

Flores-Diaz D, Arce C, Flores-Luna L, Reynoso-Noveron N, Lara-Medina F, Matus J . Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients. Breast Cancer Res Treat. 2019; 176(1):243-249. DOI: 10.1007/s10549-019-05234-8. View

Arpino G, Bardou V, Clark G, Elledge R . Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004; 6(3):R149-56. PMC: 400666. DOI: 10.1186/bcr767. View

Winchester D, Chang H, Graves T, Menck H, Bland K, WINCHESTER D . A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. J Am Coll Surg. 1998; 186(4):416-22. DOI: 10.1016/s1072-7515(98)00051-9. View

Lambein K, Praet M, Forsyth R, Van den Broecke R, Braems G, Matthys B . Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations. J Clin Pathol. 2010; 64(3):200-7. DOI: 10.1136/jcp.2010.084863. View

Silverstein M, Lewinsky B, Waisman J, Gierson E, Colburn W, Senofsky G . Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma?. Cancer. 1994; 73(6):1673-7. DOI: 10.1002/1097-0142(19940315)73:6<1673::aid-cncr2820730620>3.0.co;2-b. View

Mate T, Carter D, Fischer D, Hartman P, MCKHANN C, Merino M . A clinical and histopathologic analysis of the results of conservation surgery and radiation therapy in stage I and II breast carcinoma. Cancer. 1986; 58(9):1995-2002. DOI: 10.1002/1097-0142(19861101)58:9<1995::aid-cncr2820580907>3.0.co;2-1. View

Zengel B, Yararbas U, Duran A, Uslu A, Eliyatkin N, Demirkiran M . Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast. Breast Cancer. 2013; 22(4):374-81. DOI: 10.1007/s12282-013-0489-8. View

Garcia-Fernandez A, Lain J, Chabrera C, Garcia Font M, Fraile M, Barco I . Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival. Breast J. 2015; 21(5):533-7. DOI: 10.1111/tbj.12455. View

10.

Molland J, Donnellan M, Janu N, Carmalt H, Kennedy C, Gillett D . Infiltrating lobular carcinoma--a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast. 2004; 13(5):389-96. DOI: 10.1016/j.breast.2004.03.004. View

11.

Li C, Anderson B, Daling J, Moe R . Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003; 289(11):1421-4. DOI: 10.1001/jama.289.11.1421. View

12.

Corona S, Bortul M, Scomersi S, Bigal C, Bottin C, Zanconati F . Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers. Breast Cancer Res Treat. 2020; 180(3):735-745. DOI: 10.1007/s10549-020-05565-x. View

13.

Biglia N, Maggiorotto F, Liberale V, Bounous V, Sgro L, Pecchio S . Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Eur J Surg Oncol. 2013; 39(5):455-60. DOI: 10.1016/j.ejso.2013.02.007. View

14.

Allred D, Clark G, Elledge R, Fuqua S, Brown R, Chamness G . Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993; 85(3):200-6. DOI: 10.1093/jnci/85.3.200. View

15.

Mann R, Hoogeveen Y, Blickman J, Boetes C . MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Res Treat. 2007; 107(1):1-14. PMC: 2096637. DOI: 10.1007/s10549-007-9528-5. View

16.

Burstein H, Lacchetti C, Anderson H, Buchholz T, Davidson N, Gelmon K . Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 37(5):423-438. DOI: 10.1200/JCO.18.01160. View

17.

McCart Reed A, Kutasovic J, Lakhani S, Simpson P . Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. Breast Cancer Res. 2015; 17:12. PMC: 4310190. DOI: 10.1186/s13058-015-0519-x. View

18.

Li C, Daling J . Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev. 2007; 16(12):2773-80. DOI: 10.1158/1055-9965.EPI-07-0546. View

19.

Wasif N, Maggard M, Ko C, Giuliano A . Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol. 2010; 17(7):1862-9. DOI: 10.1245/s10434-010-0953-z. View

20.

Marmor S, Hui J, Huang J, Kizy S, Beckwith H, Blaes A . Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer. 2017; 123(16):3015-3021. DOI: 10.1002/cncr.30699. View